Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Radiotherapy in Advanced NSCLC
NCT03644823Phase 2Terminated
- Sponsor
- Oslo University Hospital
- Start
- Aug 2018
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Oslo University Hospital. Primary endpoint: Incidence, nature, and severity of adverse events at 24 months. Started Aug 2018; status: terminated.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03644823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03644823.